467 related articles for article (PubMed ID: 23087179)
21. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial.
Cascavilla N; Bisceglia M; D'Arena G
Int J Immunopathol Pharmacol; 2010; 23(2):633-6. PubMed ID: 20646359
[TBL] [Abstract][Full Text] [Related]
23. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review.
Besada E; Nossent H
Clin Rheumatol; 2010 May; 29(5):567-71. PubMed ID: 20119842
[TBL] [Abstract][Full Text] [Related]
24. Partial response to cyclosporine in a patient with Schnitzler's syndrome.
Carbone J; Paravisini A; Sarmiento E; Rodríguez-Molina J; Fernández-Cruz E
Allergol Immunopathol (Madr); 2007; 35(2):71-3. PubMed ID: 17428403
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of Schnitzler syndrome with canakinumab.
Pesek R; Fox R
Cutis; 2014 Sep; 94(3):E11-2. PubMed ID: 25279482
[No Abstract] [Full Text] [Related]
26. A man in his fifties with recurrent urticaria, fever and joint pain.
Simonsen HE; Berkman R; Skorpen PK; Hallstensen RF; Aukrust P
Tidsskr Nor Laegeforen; 2022 Mar; 142(4):. PubMed ID: 35239264
[TBL] [Abstract][Full Text] [Related]
27. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
[TBL] [Abstract][Full Text] [Related]
28. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
[TBL] [Abstract][Full Text] [Related]
29. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
30. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
31. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
Curran MP
BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
[TBL] [Abstract][Full Text] [Related]
32. Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome.
de Koning HD; van Vlijmen-Willems IM; Rodijk-Olthuis D; van der Meer JW; Zeeuwen PL; Simon A; Schalkwijk J
Br J Dermatol; 2015 Aug; 173(2):448-56. PubMed ID: 25904179
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
[TBL] [Abstract][Full Text] [Related]
34. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease?
Migliorini P; Del Corso I; Tommasi C; Boraschi D
Eur Cytokine Netw; 2009 Sep; 20(3):108-11. PubMed ID: 19825519
[TBL] [Abstract][Full Text] [Related]
35. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
[TBL] [Abstract][Full Text] [Related]
36. Schnitzler's syndrome treated successfully with intravenous pulse cyclophosphamide.
Peterlana D; Puccetti A; Tinazzi E; Simeoni S; Lunardi C
Scand J Rheumatol; 2005; 34(4):328-30. PubMed ID: 16195169
[TBL] [Abstract][Full Text] [Related]
37. An unusual presentation of immunoglobulin A gammopathy in a patient with Schnitzler's syndrome.
Kaganov E; Jhaveri D; Peters P; IJdo JW
Int J Rheum Dis; 2023 Oct; 26(10):2085-2088. PubMed ID: 37191194
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.
Betrains A; Staels F; Vanderschueren S
Semin Arthritis Rheum; 2020 Aug; 50(4):636-642. PubMed ID: 32502728
[TBL] [Abstract][Full Text] [Related]
39. Schnitzler's syndrome: successful treatment with anakinra.
Crouch R; Akhras V; Sarkany R
Australas J Dermatol; 2007 Aug; 48(3):178-81. PubMed ID: 17680970
[TBL] [Abstract][Full Text] [Related]
40. Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation.
Bonnekoh H; Scheffel J; Wu J; Hoffmann S; Maurer M; Krause K
Front Immunol; 2019; 10():546. PubMed ID: 30967871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
